Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?

ISSN: 2212-4071 (Online)
ISSN: 1574-891X (Print)


Volume 9, 3 Issues, 2014


Download PDF Flyer




Recent Patents on Anti-Infective Drug Discovery

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Dieter Kabelitz
Institute of Immunology
Universitätsklinikum Schleswig-Holstein
Campus Kiel
Arnold-Heller-Straße 3
Kiel, D-24105
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?

Author(s): Antonio Di Biagio, Roberta Prinapori, Lucia Taramasso, Giulia Gustinetti, Laura Sticchi, Bianca Bruzzone and Claudio Viscoli

Affiliation: InfectiousDiseases Unit, IRCCS A.O.U. San Martino- IST, Genoa, Italy, Largo R. Benzi, 10, 16132 Genoa, Italy.

Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.

Keywords: Cobicistat, elvitegravir, emtricitabine, resistance, side effects, tenofovirDF.

Download Free Rights and Permissions

  
  



Article Details

Volume: 9
Issue Number: 1
First Page: 41
Last Page: 51
Page Count: 11
DOI: 10.2174/1574891X09666140717102358
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science